Body Protective Compound-157, commonly known as BPC-157, is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Since its isolation and characterization in the 1990s, it has become one of the most extensively studied peptides in preclinical research, attracting significant interest from the scientific community for its apparent role in accelerating tissue repair and modulating inflammatory pathways.
What Is BPC-157?
BPC-157 is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that does not occur naturally in this form in the human body, but is derived from a partial sequence of the Body Protection Compound found in gastric juice. It is classified as a research peptide and is not approved by the FDA for human therapeutic use. All research involving BPC-157 is conducted in preclinical settings.
Studied Mechanisms of Action
Preclinical studies have identified several mechanisms through which BPC-157 appears to exert its effects on tissue repair:
Angiogenesis promotion. Multiple studies have demonstrated that BPC-157 upregulates VEGF (Vascular Endothelial Growth Factor) expression, which plays a central role in the formation of new blood vessels. Improved vascularization is considered a critical factor in accelerating healing of tendons, ligaments, and muscle tissue, which are notoriously slow to heal due to their relatively poor blood supply.
Nitric oxide pathway modulation. Research published in peer-reviewed journals has shown that BPC-157 interacts with the nitric oxide (NO) system, which regulates vascular tone and inflammatory signaling. This interaction is thought to contribute to its observed cytoprotective effects in gastric and intestinal tissue models.
Tendon fibroblast stimulation. Studies using in vitro tendon fibroblast cultures have found that BPC-157 significantly increases the outgrowth and proliferation of tendon fibroblasts — the cells responsible for producing collagen and repairing connective tissue. This finding has made BPC-157 a subject of particular interest in musculoskeletal injury research.
Growth hormone receptor upregulation. Some research suggests BPC-157 may sensitize tissue to growth hormone signaling, potentially amplifying the body’s natural repair processes without directly introducing exogenous growth hormone.
Summary of Key Preclinical Research Areas
The following table summarizes the primary injury models studied in BPC-157 preclinical research:
| Injury Model | Observed Effect in Studies | Key Reference Area |
|---|---|---|
| Achilles tendon transection | Accelerated tendon-to-bone healing | Tendon repair |
| Rotator cuff tear (rat model) | Improved collagen organization | Shoulder/rotator cuff |
| Muscle crush injury | Faster functional recovery | Skeletal muscle |
| Ligament damage (MCL) | Enhanced fibroblast activity | Ligament repair |
| Gastric ulcer | Cytoprotective effect | GI tissue |
| Spinal cord injury | Neuroprotective effects observed | CNS/nerve tissue |
| Bone fracture | Improved callus formation | Bone healing |
It is important to note that the overwhelming majority of BPC-157 research has been conducted in rodent models. Human clinical trials remain limited, and researchers should interpret preclinical findings with appropriate scientific caution.
Administration Routes Studied in Research
Preclinical research has examined BPC-157 administered via several routes, including subcutaneous injection, intramuscular injection, intraperitoneal injection, and oral gavage. Studies have found that BPC-157 appears to retain activity when administered orally in animal models, which is unusual for peptides (which are typically degraded in the GI tract). This property has made it a subject of interest in gastrointestinal research specifically.
For subcutaneous and intramuscular administration, researchers typically use reconstituted lyophilized powder dissolved in bacteriostatic water. Proper sterile technique and appropriate storage conditions (refrigerated, protected from light) are essential for maintaining peptide integrity.
Purity and Quality Considerations for Research
The quality of BPC-157 used in research directly affects the validity and reproducibility of results. Researchers sourcing BPC-157 should look for vendors who provide third-party Certificate of Analysis (COA) from an independent laboratory confirming peptide identity, purity (ideally ≥99%), and the absence of contaminants; HPLC (High-Performance Liquid Chromatography) testing to verify purity percentage; mass spectrometry verification to confirm the correct molecular weight and sequence; and sterility testing for injectable-grade preparations.
Wellington Reserve supplies BPC-157 with a minimum purity of ≥99%, verified by independent third-party HPLC and mass spectrometry analysis. All COAs are available for review prior to purchase at wellingtoncompounds.com.
Important Research Disclaimer
BPC-157 is sold strictly for research purposes. It is not intended for human consumption, is not approved by the FDA for therapeutic use, and should only be handled by qualified researchers in appropriate laboratory settings. All information in this article is provided for educational and research reference purposes only.
Wellington Reserve is a supplier of research-grade peptides for qualified researchers. All products are third-party tested and accompanied by a Certificate of Analysis. Visit wellingtoncompounds.com to view our full catalog and COA documentation.